Literature DB >> 18813132

Policy considerations in designing a fragile X population screening program.

Lainie Friedman Ross1, Kruti Acharya.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18813132      PMCID: PMC3632081          DOI: 10.1097/GIM.0b013e3181889457

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


× No keyword cloud information.
  22 in total

1.  Changing perspectives on the benefits of newborn screening.

Authors:  Donald B Bailey; Laura M Beskow; Arlene M Davis; Debra Skinner
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2006

2.  ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities.

Authors: 
Journal:  Obstet Gynecol       Date:  2007-01       Impact factor: 7.661

3.  Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening.

Authors: 
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

4.  ACOG committee opinion. No. 338: Screening for fragile X syndrome.

Authors: 
Journal:  Obstet Gynecol       Date:  2006-06       Impact factor: 7.661

5.  California's experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry.

Authors:  Lisa Feuchtbaum; Fred Lorey; Lisa Faulkner; John Sherwin; Robert Currier; Ajit Bhandal; George Cunningham
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

6.  Development of a novel, accurate, automated, rapid, high-throughput technique suitable for population-based carrier screening for Fragile X syndrome.

Authors:  Charles M Strom; Donghui Huang; Yuanyin Li; Feras M Hantash; Jenny Rooke; Steven J Potts; Weimin Sun
Journal:  Genet Med       Date:  2007-04       Impact factor: 8.822

7.  Disparity in prenatal care among women of colour in the USA.

Authors:  Jeong-Hwan Park; Deborah Vincent; Marie Hastings-Tolsma
Journal:  Midwifery       Date:  2006-07-13       Impact factor: 2.372

8.  A place for genetic uncertainty: parents valuing an unknown in the meaning of disease.

Authors:  Ian Whitmarsh; Arlene M Davis; Debra Skinner; Donald B Bailey
Journal:  Soc Sci Med       Date:  2007-06-11       Impact factor: 4.634

9.  Cost and effectiveness of the California triple marker prenatal screening program.

Authors:  G C Cunningham; D G Tompkinison
Journal:  Genet Med       Date:  1999 Jul-Aug       Impact factor: 8.822

10.  Fragile X syndrome detection in newborns-pilot study.

Authors:  Robert A Saul; Michael Friez; Karissa Eaves; Gail A Stapleton; Julianne S Collins; Charles E Schwartz; Roger E Stevenson
Journal:  Genet Med       Date:  2008-10       Impact factor: 8.822

View more
  6 in total

1.  Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers.

Authors:  Emily C Lisi; Shawn E McCandless
Journal:  J Genet Couns       Date:  2015-08-29       Impact factor: 2.537

2.  Parents' decisions to screen newborns for FMR1 gene expansions in a pilot research project.

Authors:  Debra Skinner; Summer Choudhury; John Sideris; Sonia Guarda; Allen Buansi; Myra Roche; Cynthia Powell; Donald B Bailey
Journal:  Pediatrics       Date:  2011-05-29       Impact factor: 7.124

3.  Fragile X screening: attitudes of genetic health professionals.

Authors:  Kruti Acharya; Lainie Friedman Ross
Journal:  Am J Med Genet A       Date:  2009-02-15       Impact factor: 2.802

4.  Developmental and behavioral pediatricians' attitudes toward screening for fragile X.

Authors:  Kruti Acharya; Abigail Schindler
Journal:  Am J Intellect Dev Disabil       Date:  2013-07

5.  Caregiver opinions about fragile X population screening.

Authors:  Donald B Bailey; Ellen Bishop; Melissa Raspa; Debra Skinner
Journal:  Genet Med       Date:  2011-09-13       Impact factor: 8.822

Review 6.  Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders.

Authors:  Indhu-Shree Rajan-Babu; Samuel S Chong
Journal:  Genes (Basel)       Date:  2016-10-14       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.